📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. (2020)

First Author: Kolinsky MP

Attributed to: BAG-1: A novel strategy for targeting the androgen receptor splice variants in castrate resistant prostate cancer. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.annonc.2020.01.074

PubMed Identifier: 32205016

Publication URI: http://europepmc.org/abstract/MED/32205016

Type: Journal Article/Review

Volume: 31

Parent Publication: Annals of oncology : official journal of the European Society for Medical Oncology

Issue: 5

ISSN: 0923-7534